Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose intensive nab-paclitaxel plus nutrition in malnourished upper gastrointestinal cancer
ChiCTR2000038940Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nab-paclitaxel in gastric cancer (GC), esophageal cancer and upper gastrointestinal cancer, sponsored by Anhui Provincial Tumor Hospital. Primary endpoints: Objective response rate (ORR), Nutritional status assessment (PG-SGA score) and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
gastric cancer (GC)esophageal cancerupper gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2000038940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038940.